As of November 6, 2026, Kezar Life Sciences, Inc. has Schedule 13D or 13G filings on record, none whose latest reports a stake of 5% or more. 10 filings are on record since September 8, 2025 (Schedule 13G/A, May 28, 2026).
Sell to companies like Kezar Life Sciences, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Holder: Baselake Partners, LP · Percent: 0% · SCHEDULE 13G/A
- · Holder: Tang Capital Management, LLC · Percent: 0% · SCHEDULE 13D/A
- · Holder: BML Investment Partners, L.P. · Percent: 0% · SCHEDULE 13G/A
- · Holder: Baselake Partners, LP · Percent: 0% · SCHEDULE 13G/A
- · Holder: Baselake Partners, LP · Percent: 5.3% · SCHEDULE 13G
Kezar Life Sciences, Inc. has 10 Schedule 13D or 13G filings on record since 2025-09-08. No holder's latest filing reports 5% or more. Each figure below is the holder's own, as filed, with the filing linked.
Layoffs on record: about 31 jobs, latest 2025-11-07 (layoff filings and notices).
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Stonepine Capital Management, LLC | 2.1% | 156,179 | SCHEDULE 13G/A, 2026-02-13 | 2025-12-31 |
| Avidity Partners Management LP | 0% | 0 | SCHEDULE 13G/A, 2025-11-14 | 2025-09-30 |
| BML Investment Partners, L.P. | 0% | 0 | SCHEDULE 13G/A, 2026-05-12 | 2026-05-11 |
| Tang Capital Management, LLC | 0% | 0 | SCHEDULE 13D/A, 2026-05-13 | 2026-05-11 |
| Baselake Partners, LP | 0% | 0 | SCHEDULE 13G/A, 2026-05-28 | 2026-05-11 |
Holding shares or following this stake? See who's behind Kezar Life Sciences, Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on Kezar Life Sciences, Inc. and the records around it.
Kezar Life Sciences, Inc. elsewhere on the record
- Acquisition May 2026
- Layoff notices Nov 2025
Companies that share a holder
- Avidity Partners Management LP also filed stake reports on 5 other companies: Context Therapeutics Inc. (May 2026), Immunic, Inc. (Apr 2026), Perspective Therapeutics, Inc. (Mar 2026)
- Baselake Partners, LP also filed stake reports on 7 other companies: KIORA PHARMACEUTICALS, INC. (Sep 2026), Passage Bio, Inc. (Jun 2026), Generation Bio Co. (Feb 2026)
- BML Investment Partners, L.P. also filed stake reports on 15 other companies: LENZ Therapeutics, Inc. (Nov 2026), Seer, Inc. (Nov 2026), Connect Biopharma Holdings Ltd (Oct 2026)
Watch Kezar Life Sciences, Inc.
Get an email when Kezar Life Sciences, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Kezar Life Sciences, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Kezar Life Sciences, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Kezar Life Sciences, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
13 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Purpose of Transaction (Item 4)
Tang Capital Management, LLC
Item 4 of the Original Schedule 13D is hereby amended to add the following: Closing of the Merger: On May 11, 2026, the Issuer completed its merger with Aurinia Pharma U.S., Inc. ("Parent") and Parent's wholly-owned subsidiary, Aurinia Merger Sub, Inc. ("Merger Sub") pursuant to the terms of the Merger Agreement, whereby Merger Sub merged with and into the Issuer, in accordance with the General Corporation Law of the State of Delaware, with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the Merger Agreement, on May 11, 2026, each issued and outstanding share of the Issuer's Common Stock was cancelled.Item 4 of the SCHEDULE 13D/A filed 2026-05-13
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-09-08 | Stonepine Capital Management, LLC | 5.2% | SCHEDULE 13G |
| 2025-11-14 | Avidity Partners Management LP | 0% | SCHEDULE 13G/A |
| 2026-02-09 | BML Investment Partners, L.P. | 9.8% | SCHEDULE 13G/A |
| 2026-02-13 | Stonepine Capital Management, LLC | 2.1% | SCHEDULE 13G/A |
| 2026-04-01 | Tang Capital Management, LLC | 9% | SCHEDULE 13D/A |
| 2026-04-06 | Baselake Partners, LP | 5.3% | SCHEDULE 13G |
| 2026-05-12 | BML Investment Partners, L.P. | 0% | SCHEDULE 13G/A |
| 2026-05-12 | Baselake Partners, LP | 0% | SCHEDULE 13G/A |
| 2026-05-13 | Tang Capital Management, LLC | 0% | SCHEDULE 13D/A |
| 2026-05-28 | Baselake Partners, LP | 0% | SCHEDULE 13G/A |
Also on the record for Kezar Life Sciences, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| May 11, 2026 | Acquired by Aurinia Pharma U.S., Inc. | — | Acquisition | Source |
| May 11, 2026 | Leadership change filing (Form 8-K, Item 5.02) | — | Leadership changes | Source |
| April 3, 2026 | Leadership change filing (Form 8-K, Item 5.02) | — | Leadership changes | Source |
Tools for this story
Each opens in a new tab, filled in for Kezar Life Sciences, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.